Harpreet Singh, Chief Medical Officer of Precision for Medicine, shared on LinkedIn:
“The recent KRASCENDO-1 update marks an important moment in KRAS G12C-mutated NSCLC.
In this quick hit video, I share why the trial design stands out. Rather than comparing divarasib with docetaxel, Roche Genentech designed the study against approved KRAS G12C inhibitors, sotorasib or adagrasib.
KRASCENDO-1 met its primary endpoint and improved both progression-free and overall survival, and now the focus shifts to the detailed efficacy, safety, and tolerability results from this head-to-head comparison.
As KRAS G12C development continues to evolve, this is the kind of study design that can help define what the next generation of targeted therapies needs to show.”
Other articles about lung cancer on OncoDaily.